Liver transaminase levels alone could not be the optimal method to estimate hepatic safety after statin administration in patients with chronic kidney disease
- PMID: 21742076
- DOI: 10.1016/j.ahj.2011.04.024
Liver transaminase levels alone could not be the optimal method to estimate hepatic safety after statin administration in patients with chronic kidney disease
Comment on
-
Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.Am Heart J. 2010 Nov;160(5):785-794.e10. doi: 10.1016/j.ahj.2010.08.012. Epub 2010 Sep 18. Am Heart J. 2010. PMID: 21095263 Clinical Trial.
Similar articles
-
Statin effects in CKD: is there a "point of no return"?Am J Kidney Dis. 2009 May;53(5):723-5. doi: 10.1053/j.ajkd.2009.02.002. Am J Kidney Dis. 2009. PMID: 19393469 No abstract available.
-
Impact of statin dosing intensity on transaminase and creatine kinase.Am J Med. 2008 Feb;121(2):e11; author reply e13. doi: 10.1016/j.amjmed.2007.09.018. Am J Med. 2008. PMID: 18261479 No abstract available.
-
Safety of statin therapy in patients with preexisting liver disease.Pharmacotherapy. 2008 Apr;28(4):522-9. doi: 10.1592/phco.28.4.522. Pharmacotherapy. 2008. PMID: 18363535 Review.
-
The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients.Clin J Am Soc Nephrol. 2011 Mar;6(3):664-78. doi: 10.2215/CJN.09091010. Epub 2011 Mar 10. Clin J Am Soc Nephrol. 2011. PMID: 21393488 Review.
-
Statins and the liver.Cardiol Clin. 2015 May;33(2):257-65. doi: 10.1016/j.ccl.2015.02.005. Cardiol Clin. 2015. PMID: 25939298 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical